Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Taxes: 2024-2025

  • BridgeBio Pharma's Current Taxes was N/A to $2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that BridgeBio Pharma reported Current Taxes of $2.1 million as of Q2 2025, which was up 82.13% from $1.2 million recorded in Q4 2024.
  • In the past 5 years, BridgeBio Pharma's Current Taxes registered a high of $2.1 million during Q2 2025, and its lowest value of $1.2 million during Q4 2024.
  • For the 2-year period, BridgeBio Pharma's Current Taxes averaged around $1.6 million, with its median value being $1.6 million (2024).